A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
Key Details
- 1Study involved 216 women with breast cancer post-neoadjuvant chemotherapy.
- 2Model integrated MRI radiomics, pathology, and clinical data using deep learning.
- 3The deep feature-based patho-radiomic model achieved AUCs of 0.89 (training) and 0.82 (test) for 5-year survival, and 0.91 (training) and 0.87 (test) for 7-year survival.
- 4Clinical-only models showed lower AUCs (0.4–0.53 for 5-years; 0.45–0.53 for 7-years).
- 5Traditional clinical and molecular markers (ER, HER2, TNBC) did not significantly predict survival in this cohort.
- 6Authors advocate for prospective studies to guide clinical decisions using the model.
Why It Matters
This research demonstrates the power of combining imaging, pathology, and clinical data through AI to provide more accurate long-term prognostic tools in oncology, surpassing traditional clinical or single-modality models. Improved risk stratification could optimize therapeutic decision-making and patient counseling in breast cancer care.
Source
AuntMinnie
Related News
•Radiology Business
AI-Powered Tool Streamlines CT Scan Prioritization in Emergency Departments
An AI-based CT queue system significantly reduces wait times for ED patients by prioritizing scans likely to reveal critical findings.
•Radiology Business
AI Workflow Enables General Radiologists to Match Breast Specialists in Screening
AI-powered workflow helps generalist radiologists detect breast cancer at rates comparable to specialists.
•Radiology Business
LLMs Automate Radiology Report Quality Control, Study Finds
LLM-based systems can rapidly automate radiology report quality control, saving significant manual review time.